Coagulation/Hemostasis Nonhuman Primates Disease Model

Coagulation is a highly regulated process that plays a critical role in preventing blood loss after injury. However, when the body is in a pro-coagulant state, it can contribute to occlusive diseases of both the arterial and venous systems. At Prisys Biotechnologies, we have developed several in vivo models and assays that enable us to identify dynamic changes in the body's hemostasis status. These endpoints are critical for pharmacology and safety assessments in vascular disease models.

Our NHP models include the In vivo Bleeding model, Arterio-Venous (A-V) shunt model, Wessler stasis model, and FeCl3 induced arterial thrombosis model. The standard study duration for these models is hours, with study endpoints determined by the specific experimental design. Clinical endpoints include bleeding time/weight, thrombus/clot weight, coagulation tests, blood flow velocity, and thrombelastography.

Our models are designed to provide comprehensive hemostasis assessments, safety assessments, antithrombotic studies, coagulation factor studies, and intravital thrombosis evaluations. These models enable us to gain a deeper understanding of the underlying mechanisms of coagulation and thrombosis, and provide a powerful tool for developing and testing new therapies for vascular diseases.

Hot Tags: coagulation/hemostasis nonhuman primates disease model, research, study, monkey, gene therapy, NHP NASH Model, NHP COPD Model, Nonhuman Primates Disease Model, RNA PK pharmacology, veterinary PK, NHP Chronic Obstructive Pulmonary Disease Model